Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(26 sites)

China

The First Hospital of Jilin University, Changchun

Sichuan Provincial People's Hospital, Chengdu

Dongguan People's Hospital, Dongguan

Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang People's hospital, Dongyang

The First People's Hospital of Foshan, Foshan

Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou

Nanfang Hospital, Southern Medical University, Guangzhou

Sun Yat-sen University cancer center, Guangzhou

The First Affiliated Hospital, Sun Yat-sen University, Guangzhou

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou

Zhejiang Provincial Hospital of Chinese Medicine, Hangzhou

Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun Yat-sen University, Jiangmen

Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua

Mianyang Central Hospital, Mianyang

The First Affiliated Hospital of Nanchang University, Nanchang

Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang

Shijiazhuang People's hospital, Shijiazhuang

The Affiliated Cancer Hospital of Xinjiang Medical University, Ürümqi

The Third Affiliated Hospital of Wenzhou Medical University, Rui'an People's Hospital, Wenzhou

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

Yijishan Hospital, Wannan Medical College, Wuhu

Tangdu Hospital, Fourth Military Medical University, Xi'an

The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an

The Affiliated Hospital of Xuzhou Medical University, Xuzhou

The First Affiliated Hospital of Zhengzhou University, Zhengzhou